Chemotherapy and supportive medications such as dexamethasone can disrupt glucose regulation in patients with breast cancer. Continuous glucose monitoring revealed that all patients with early-stage breast cancer experienced hyperglycemia during treatment, but the duration and severity varied dramatically by baseline glucose status, with prediabetes or diabetes associated with substantially more time spent hyperglycemic.